<--- Back to Details
First PageDocument Content
Orphan drugs / Amines / Food and Drug Administration / Clinical research / Pharmacology / Omacetaxine mepesuccinate / Pixantrone / Chronic myelogenous leukemia / Dasatinib / Chemistry / Medicine / Organic chemistry
Orphan drugs
Amines
Food and Drug Administration
Clinical research
Pharmacology
Omacetaxine mepesuccinate
Pixantrone
Chronic myelogenous leukemia
Dasatinib
Chemistry
Medicine
Organic chemistry

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 114,67 KB

Share Document on Facebook

Similar Documents

Pyrimidines / Piperazines / Medicine / Pyridines / Organofluorides / Chronic myelogenous leukemia / Dasatinib / Omacetaxine mepesuccinate / Imatinib / Organic chemistry / Chemistry / Orphan drugs

FDA Review NDA[removed]Omapro™ (omacetaxine mepesuccinate) ODAC March 22, 2010 Amy McKee, M.D.

DocID: GfBD - View Document

Pyrimidines / Piperazines / Medicine / Pyridines / Organofluorides / Chronic myelogenous leukemia / Omacetaxine mepesuccinate / Dasatinib / Philadelphia chromosome / Organic chemistry / Orphan drugs / Chemistry

Microsoft Word - ODAC briefing book 07JAN2010 FINAL

DocID: GcWw - View Document

Myeloid leukemia / Pyrimidines / Biology / Orphan drugs / Organic chemistry / Imatinib / Abl gene / Omacetaxine mepesuccinate / Philadelphia chromosome / Piperazines / Medicine / Chronic myelogenous leukemia

Microsoft PowerPoint - 1 Core Introduction (CI) FINAL

DocID: G22y - View Document

ChemGenex Pharmaceuticals OMAPRO™ (omacetaxine mepesuccinate) ODAC Briefing Book Errata

DocID: FzZu - View Document

Orphan drugs / Omacetaxine mepesuccinate

Microsoft Word - ODAC briefing book Errata #2 page 51

DocID: FnHN - View Document